GlobeNewswire: Vaccinex, Inc. Contains the last 10 of 117 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T23:42:56ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853151/0/en/Vaccinex-Inc-Announces-1-5-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-At-the-Market-Under-Nasdaq-Rules.html?f=22&fvtc=4&fvtv=24988Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules2024-03-27T12:30:00Z<![CDATA[ROCHESTER, N.Y., March 27, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease and cancer through the inhibition of SEMA4D, today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of 193,000 shares of its common stock in a registered direct offering together with warrants to purchase up to an aggregate of 193,000 shares of common stock in a concurrent private placement priced at-the-market under Nasdaq rules at a combined purchase price of $7.77 per share and accompanying warrant. The warrants will have an exercise price of $7.64 per share, will be immediately exercisable upon issuance and will expire 5 years from the initial exercise date. The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”]]>https://www.globenewswire.com/news-release/2024/02/21/2832705/0/en/Vaccinex-Announces-Multiple-New-Agreements-for-Access-to-ActivMAb-Antigen-Virus-Technology.html?f=22&fvtc=4&fvtv=24988Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology2024-02-21T13:00:00Z<![CDATA[Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform]]>https://www.globenewswire.com/news-release/2024/02/15/2829923/0/en/Vaccinex-Inc-Announces-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=24988Vaccinex, Inc. Announces Reverse Stock Split2024-02-15T13:00:00Z<![CDATA[ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. Beginning Tuesday, February 20, 2024, the Company's common stock will trade on a split-adjusted basis.]]>https://www.globenewswire.com/news-release/2024/02/07/2825160/0/en/Vaccinex-Announces-Pricing-of-3-7-Million-PIPE-Financing.html?f=22&fvtc=4&fvtv=24988Vaccinex Announces Pricing of $3.7 Million PIPE Financing2024-02-07T13:00:00Z<![CDATA[ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced it has priced a $3.7 million private placement transaction with a lead investment from a major new investor alongside significant participation from existing investors, including entities affiliated with the Chairman of the Company’s Board of Directors and the Company’s Chief Executive Officer. The securities purchase agreement for the financing provides for the sale of an aggregate of 3,838,544 shares of the Company’s common stock (and 1,265,078 common stock equivalents in lieu of common stock) together with common warrants to purchase up to an equal number (5,103,622) of shares of common stock. The shares and warrants are being sold at a combined purchase price per share and warrant of $0.725. The common warrants will have an exercise price of $1.00 per share. The common warrants will be immediately exercisable and will expire five years from the initial exercise date, provided, however, that the Company may call the warrants within 120 days after reporting specified positive topline data in the Company’s ongoing SIGNAL-AD phase 1/2a clinical trial of its lead drug candidate, pepinemab, in Alzheimer’s disease.]]>https://www.globenewswire.com/news-release/2023/12/04/2789961/0/en/Nasdaq-Grants-Vaccinex-Extension-Until-March-4-2024-to-Regain-Compliance-with-Listing-Rule.html?f=22&fvtc=4&fvtv=24988Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule2023-12-04T13:00:00Z<![CDATA[Company Has Reassured Nasdaq of Actions It Plans to Take to Meet Minimum Bid Price Requirement]]>https://www.globenewswire.com/news-release/2023/11/13/2778973/0/en/Vaccinex-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=24988Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update2023-11-13T13:00:00Z<![CDATA[Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual]]>https://www.globenewswire.com/news-release/2023/10/31/2770272/0/en/Vaccinex-Reports-Clinical-Benefit-in-Interim-Analyses-from-two-Phase-2-Studies-of-Pepinemab-Combination-Treatment-at-Society-for-Immunotherapy-of-Cancer-s-Annual-Meeting.html?f=22&fvtc=4&fvtv=24988Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting2023-10-31T13:00:00Z<![CDATA[Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanoma Pepinemab, anti-SEMA4D blocking antibody, appears to enhance clinical activity of immune checkpoint inhibitors via induction of highly organized tertiary immune structures in tumors of patients with head and neck cancer and melanoma]]>https://www.globenewswire.com/news-release/2023/10/26/2767669/0/en/Vaccinex-Reports-Positive-Effect-of-Pepinemab-Treatment-on-New-Biomarker-of-Brain-Inflammation-in-Neurodegenerative-Diseases.html?f=22&fvtc=4&fvtv=24988Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases2023-10-26T13:30:00Z<![CDATA[Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood]]>https://www.globenewswire.com/news-release/2023/09/29/2751717/0/en/Vaccinex-Announces-Pricing-of-9-6-Million-Public-Offering.html?f=22&fvtc=4&fvtv=24988Vaccinex Announces Pricing of $9.6 Million Public Offering2023-09-29T01:00:00Z<![CDATA[ROCHESTER, N.Y., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced it has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company’s Board of Directors, and existing investors of the Company for the purchase and sale of 9,600,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 9,600,000 shares of common stock at a purchase price per share (and accompanying warrant) of $1.00 in its "reasonable best efforts" public offering. The warrants will have an exercise price of $1.00 per share, will be immediately exercisable and will expire five years from the initial exercise date.]]>https://www.globenewswire.com/news-release/2023/09/28/2751172/0/en/Vaccinex-s-Next-Generation-ActivMAb-Technology-Published-in-mAbs-a-Leading-Biotech-Journal-and-Validated-in-OmniAb-Proof-of-Concept-Collaboration.html?f=22&fvtc=4&fvtv=24988Vaccinex’s Next Generation ActivMAb® Technology Published in mAbs, a Leading Biotech Journal, and Validated in OmniAb Proof-of-Concept Collaboration2023-09-28T12:00:00Z<![CDATA[Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their “native conformation” so as to efficiently induce and select specific antibody-producing cells]]>